What question did this study set out to answer?

To assess the impact of ivonescimab added to chemotherapy on overall survival in patients with EGFR-variant NSCLC after prior TKI therapy.

June 19, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer

Puntos clave

To assess the impact of ivonescimab added to chemotherapy on overall survival in patients with EGFR-variant NSCLC after prior TKI therapy.
Randomized, double-blind, placebo-controlled phase 3 trial conducted at 55 sites in China with 322 patients.
Patients received ivonescimab or placebo plus chemotherapy (pemetrexed and carboplatin) every 3 weeks for 4 cycles and maintenance therapy.
Primary outcome was progression-free survival; key secondary outcome was overall survival.
Patients treated with ivonescimab had a median overall survival of 16.8 months compared to 14.1 months for placebo (HR 0.74, 95% CI 0.58-0.95, P=0.02).
Estimated 30-month survival rates were 29.1% with ivonescimab versus 18.4% with placebo.
Grade 3 or higher treatment-emergent adverse events were reported in 67.1% of ivonescimab recipients compared to 54.7% for placebo.

Resumen

Importance: Patients with epidermal growth factor receptor (EGFR) gene variant nonsquamous non-small cell lung cancer (NSCLC) who have disease progression after prior EGFR tyrosine kinase inhibitor (TKI) therapy have limited treatment options, creating a need for more effective subsequent therapies. Objective: To provide final overall results of a trial assessing whether adding ivonescimab (a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor) to chemotherapy improves overall survival in this population. Design, Setting, and Participants: Randomized, double-blind, placebo-controlled phase 3 trial conducted at 55 sites in China. From January 25 to November 2, 2022, a total of 322 adult patients with locally advanced or metastatic EGFR-variant nonsquamous NSCLC who had received prior EGFR-TKI therapy were enrolled. The data cutoff date was April 12, 2025. Interventions: Patients were randomized 1:1 to receive ivonescimab (20 mg/kg; n = 161) or placebo (n = 161) plus chemotherapy with pemetrexed and carboplatin once every 3 weeks for 4 cycles, followed by maintenance therapy. Main Outcomes and Measures: This final results report focuses on overall survival, the key secondary end point, tested in a hierarchical manner (the primary end point was progression-free survival assessed by an independent radiology review committee). Results: The 322 enrolled patients had a median age of 59.4 years, and 51.6% were female. During a median follow-up of 32.5 months, ivonescimab plus chemotherapy improved overall survival compared with chemotherapy alone (median survival, 16.8 months vs 14.1 months; stratified hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02). The absolute difference in median overall survival was 2.7 months. Estimated 30-month survival rates were 29.1% (95% CI, 22.1%-36.4%) with ivonescimab and 18.4% (95% CI, 12.8%-24.8%) with placebo. Grade 3 or higher treatment-emergent adverse events occurred in 67.1% and 54.7% of patients receiving ivonescimab and placebo, respectively. Conclusions and Relevance: Ivonescimab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival with an acceptable safety profile in patients with EGFR-variant NSCLC after EGFR-TKI therapy. Trial Registration: ClinicalTrials.gov Identifier: NCT05184712.

Me gusta

Guardar